Aim The aim
of this study was to evaluate the efficacy of single-incision thoracoscopic surgery
(SITS) talc pleurodesis for malignant pleural effusion.
Material and Methods We examined the medical records of all consecutive
patients with malignant pleural effusion who underwent single port
thoracoscopic pleurodesis from 2014 to 2018 at the Health Sciences University
Antalya Practice and Research Center. There were 30 males (54.5%) and 25
females (45.4%), ranging in age from 35 to 88 years (mean age: 64.0 years). Pleurodesis
was achieved by insufflation of 4g of sterile asbestos-free talc; the chest
tube was left in place a minimum of 3 days and was removed when fluid drainage
was less than 100 ml/24 h. Patients were discharged the day after chest tube
removal and a return visit was scheduled on the 30th post-operative day, for
clinical evaluation and for a new chest radiograph. Pleurodesis was regarded as
successful if the amount of the fluid on chest radiograph on the 30th
post-operative day showed a pleural effusion occupying less than one-fourth of
the pleural space.
Results The
main causes of malignant pleural effusion were non-small cell lung carcinoma
and breast cancer. Major symptoms were dyspnea, chest pain and radiographic
findings of pleural fluid. The effusion was on the right side in 40 patients
(72.7%) and on the left side in 15 (27.2%). There was no intraoperative
mortality. The postoperative complication rate was 10.9% (6
patients), and included fever in 1.8% (one patient) and chest pain in 9.0% (5
patients) of the patients. Duration of postoperative pleural drainage ranged
between 3 and 13 days (mean: 3.36 days). The postoperative hospital stay ranged
from 3 to 15 days (mean: 5.6 days). A successful pleurodesis was achieved in 34
of 55 patients (61.8%).
Conclusion SITS talc
pleurodesis is an effective and safe treatment for the
management of malignant pleural effusion.
Aim: The aim of this study was to evaluate the efficacy of single-incision
thoracoscopic surgery (SITS) talc pleurodesis for malignant pleural effusion.
Material and Methods: We examined the medical records of all consecutive
patients with malignant pleural effusion who underwent single port
thoracoscopic pleurodesis from 2014 to 2018 at the Health Sciences University
Antalya Practice and Research Center. Therewere 30 males (54.5%) and 25 females
(45.4%), ranging in age from 35 to 88 years (mean age: 64.0 years). Pleurodesis
was achieved by insufflation of 4g of sterile asbestos-free talc; the chest
tube was left in place a minimum of 3 days and was removedwhen fluid drainage
was less than 100 ml/24 h. Patients were discharged the day after chest tube
removal and a return visit was scheduled on the 30th post-operative day, for
clinical evaluation and for a new chest radiograph. Pleurodesis was regarded as
successful if the amount of the fluid on chest radiograph on the 30th
post-operative dayshowed a pleural effusion occupying less than one-fourth of
the pleural space.
Results: The main causes of malignant pleural effusion were
non-small cell lung carcinoma and breast cancer. Major symptoms were dyspnea,
chest pain and radiographic findings of pleural fluid. The effusion was on the
right side in 40 patients (72.7%) and on the left side in 15 (27.2%). There was
no intraoperative mortality.The postoperative complication rate was 10.9% (6
patients), and includedfever in 1.8% (one patient) and chest pain in 9.0% (5
patients) of the patients.Duration of postoperative pleural drainage ranged
between 3 and 13 days (mean: 3.36 days).The postoperative hospital stay ranged
from 3 to 15 days (mean: 5.6 days). A successful pleurodesis was achieved in 34
of 55 patients (61.8%).
Conclusion:
SITS talc pleurodesis
is an effective and safe treatment for the management of malignant pleural effusion.
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Özgün Makale |
Yazarlar | |
Yayımlanma Tarihi | 28 Aralık 2018 |
Yayımlandığı Sayı | Yıl 2018 |
e-ISSN: 2149-8296
The content of this site is intended for health care professionals. All the published articles are distributed under the terms of
Creative Commons Attribution Licence,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.